Menu

Study Finds Low Trust in Vaccines in Europe

Just half of respondents in Eastern Europe agree that vaccines are safe.

Jun 19, 2019
Chia-Yi Hou

ABOVE: © ISTOCK.COM
PHICHAKLIM1

Globally, about 79 percent of people agree that vaccines are safe and 84 percent agree that they are effective, according to a survey of more than 140,000 people from about 140 countries conducted by The Wellcome Trust and published today (June 19). 

The survey “exposes the paradox of Europe,” Heidi Larson of the London School of Hygiene and Tropical Medicine who worked on the study tells Reuters. Overall, people in wealthy countries were more likely to question the safety of vaccines, while having greater knowledge of science and higher levels of education. In North America and Northern Europe, respectively, 72 percent and 73 percent of respondents said they agree that vaccines are safe. In Eastern Europe, that number is just 50 percent.

Nearly all people surveyed in Bangladesh and Rwanda agreed that vaccines are safe. France, on the other hand, had the lowest rate of trust with one in three people disagreeing with the statement that vaccines are safe.

“What’s happening in France is not the same as what’s happening in Ukraine, is not the same as what’s happening in Japan,” says Brendan Nyhan of the University of Michigan who has studied attitudes to vaccination to BuzzFeed News. In France, there is a distrust of politicians and a growing anti-vaccine movement, reports The Guardian. In Ukraine, armed conflicts have disrupted health services, according to BuzzFeed. And in Japan, concerns about a report linking the HPV vaccine to neurological problems may have lowered people’s confidence in vaccines, according to BBC News.

Vaccines are one of the most powerful public health tools, and people need to be confident in immunizations for them to be effective, says Jeremy Farrar of Wellcome in a statement accompanying the report.

“One of the most important interventions to counteract doubts and worries about vaccines is to have health workers really well trained and able and ready to recommend vaccinations based on scientific truth and to be able to respond correctly to questions and concerns that parents have and communities have,” says Ann Lindstrand of the World Health Organization to BBC.

Some countries in Eastern Europe, such as Ukraine and Belarus, have a large number of people who neither agree nor disagree that vaccines are safe and effective. “I think that’s the group that’s still open to discussion and there’s an opportunity there,” Larson tells BuzzFeed.

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

Overcoming the Efficiency Challenge in Clinical NGS
Overcoming the Efficiency Challenge in Clinical NGS
Download this white paper to see how an ECS lab serving a network of more than 10,000 healthcare providers integrated QIAGEN Clinical Insight (QCI) Interpret to significantly reduce manual variant curation efforts and increase workflow efficiency by 80%!
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas, Inc., an emerging diagnostic company, launched a portfolio of products that can improve the accuracy of current diagnostic test results by helping laboratory professionals detect and manage biotin interference in patient samples with VeraTest Biotin and VeraPrep Biotin.
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
Scientists presented more than 30 abstracts featuring Bio-Rad’s Droplet Digital PCR (ddPCR) technology at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31–June 4.
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
The National Institute Of Allergy And Infectious Disease recently awarded BellBrook Labs a $300,000 Small Business Innovative Research (SBIR) grant to develop novel inhibitors for the target cyclic GAMP Synthase (cGAS). The grant will be used to accelerate the discovery of new treatments for autoimmune diseases by targeting the cGAS-STING pathway.